These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30016917)

  • 1. Genotype scores predict drug efficacy in subtypes of female sexual interest/arousal disorder: A double-blind, randomized, placebo-controlled cross-over trial.
    Tuiten A; Michiels F; Böcker KB; Höhle D; van Honk J; de Lange RP; van Rooij K; Kessels R; Bloemers J; Gerritsen J; Janssen P; de Leede L; Meyer JJ; Everaerd W; Frijlink HW; Koppeschaar HP; Olivier B; Pfaus JG
    Womens Health (Lond); 2018; 14():1745506518788970. PubMed ID: 30016917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials.
    Tuiten A; van Rooij K; Bloemers J; Eisenegger C; van Honk J; Kessels R; Kingsberg S; Derogatis LR; de Leede L; Gerritsen J; Koppeschaar HPF; Olivier B; Everaerd W; Frijlink HW; Höhle D; de Lange RPJ; Böcker KBE; Pfaus JG
    J Sex Med; 2018 Feb; 15(2):201-216. PubMed ID: 29289554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms.
    van Rooij K; Poels S; Bloemers J; Goldstein I; Gerritsen J; van Ham D; van Mameren F; Chivers M; Everaerd W; Koppeschaar H; Olivier B; Tuiten A
    J Sex Med; 2013 Mar; 10(3):824-37. PubMed ID: 23130675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues.
    Poels S; Bloemers J; van Rooij K; Goldstein I; Gerritsen J; van Ham D; van Mameren F; Chivers M; Everaerd W; Koppeschaar H; Olivier B; Tuiten A
    J Sex Med; 2013 Mar; 10(3):810-23. PubMed ID: 23130748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.
    Kingsberg S; Shifren J; Wekselman K; Rodenberg C; Koochaki P; Derogatis L
    J Sex Med; 2007 Jul; 4(4 Pt 1):1001-8. PubMed ID: 17627745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study.
    van Rooij K; Poels S; Worst P; Bloemers J; Koppeschaar H; Goldstein A; Olivier B; Tuiten A
    Eur J Pharmacol; 2015 Apr; 753():246-51. PubMed ID: 25460030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder.
    Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Cianci A
    Urology; 2004 May; 63(5):955-9. PubMed ID: 15134988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder: A Randomized Controlled Trial.
    Johnson I; Thurman AR; Cornell KA; Hatheway J; Dart C; Brainard CP; Friend DR; Goldstein A
    Obstet Gynecol; 2024 Aug; 144(2):144-152. PubMed ID: 38889431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder.
    El-Hage G; Eden JA; Manga RZ
    Climacteric; 2007 Aug; 10(4):335-43. PubMed ID: 17653960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial comments on "the current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women".
    Goldstein I
    J Sex Med; 2008 Sep; 5 Suppl 4():177-8. PubMed ID: 18783531
    [No Abstract]   [Full Text] [Related]  

  • 11. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
    Kingsberg SA; Simon JA; Goldstein I
    J Sex Med; 2008 Sep; 5 Suppl 4():182-93; quiz 193. PubMed ID: 18783534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in pharmacotherapy for treating female sexual dysfunction.
    Nappi RE; Cucinella L
    Expert Opin Pharmacother; 2015 Apr; 16(6):875-87. PubMed ID: 25732267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.
    Simon J; Braunstein G; Nachtigall L; Utian W; Katz M; Miller S; Waldbaum A; Bouchard C; Derzko C; Buch A; Rodenberg C; Lucas J; Davis S
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5226-33. PubMed ID: 16014407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
    Davis SR; van der Mooren MJ; van Lunsen RH; Lopes P; Ribot C; Rees M; Moufarege A; Rodenberg C; Buch A; Purdie DW
    Menopause; 2006; 13(3):387-96. PubMed ID: 16735935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survival of the fittest strategy for the selection of genotypes by which drug responders and non-responders can be predicted in small groups.
    Höhle D; van Rooij K; Bloemers J; Pfaus JG; Michiels F; Janssen P; Claassen E; Tuiten A
    PLoS One; 2021; 16(3):e0246828. PubMed ID: 33667227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
    Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
    J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Tribulus Terrestris for the treatment of premenopausal women with hypoactive sexual desire disorder: a randomized double-blinded, placebo-controlled trial.
    Vale FBC; Zanolla Dias de Souza K; Rezende CR; Geber S
    Gynecol Endocrinol; 2018 May; 34(5):442-445. PubMed ID: 29172782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
    Clayton AH; Althof SE; Kingsberg S; DeRogatis LR; Kroll R; Goldstein I; Kaminetsky J; Spana C; Lucas J; Jordan R; Portman DJ
    Womens Health (Lond); 2016 Jun; 12(3):325-37. PubMed ID: 27181790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD).
    Orri M; Abraham L; Giraldi A
    J Sex Med; 2013 Oct; 10(10):2484-96. PubMed ID: 23347610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.
    Shifren JL; Davis SR; Moreau M; Waldbaum A; Bouchard C; DeRogatis L; Derzko C; Bearnson P; Kakos N; O'Neill S; Levine S; Wekselman K; Buch A; Rodenberg C; Kroll R
    Menopause; 2006; 13(5):770-9. PubMed ID: 16932240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.